

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1612RXD

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 26 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27 Oct 21 EVENTLINE has been reloaded
NEWS 28 Oct 24 BEILSTEIN adds new search fields
NEWS 29 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30 Oct 25 MEDLINE SDI run of October 8, 2002
NEWS 31 Nov 18 DKILIT has been renamed APOLLIT
NEWS 32 Nov 25 More calculated properties added to REGISTRY
NEWS 33 Dec 02 TIBKAT will be removed from STN
NEWS 34 Dec 04 CSA files on STN
NEWS 35 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36 Dec 17 TOXCENTER enhanced with additional content
NEWS 37 Dec 17 Adis Clinical Trials Insight now available on STN
NEWS 38 Dec 30 ISMEC no longer available
NEWS 39 Jan 13 Indexing added to some pre-1967 records in CA/CAPLUS

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability

Print selected from Online session13/01/2003

| | |
|------------|---|
| NEWS INTER | General Internet Information |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS PHONE | Direct Dial and Telecommunication Network Access to STN |
| NEWS WWW | CAS World Wide Web Site (general information) |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:22:17 ON 13 JAN 2003

=> file registry

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 12:22:32 ON 13 JAN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 JAN 2003 HIGHEST RN 478784-40-6
DICTIONARY FILE UPDATES: 12 JAN 2003 HIGHEST RN 478784-40-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNnote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>

Uploading 09980965.str


L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

Print selected from Online session12:24Page 2



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 ful
FULL SEARCH INITIATED 12:22:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 65908 TO ITERATE
```

```
100.0% PROCESSED 65908 ITERATIONS 188 ANSWERS
SEARCH TIME: 00.00.01
```

```
L2 188 SEA SSS FUL L1
```

```
=> file uspatall
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 148.15 148.36
```

```
FILE 'USPATFULL' ENTERED AT 12:23:04 ON 13 JAN 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

```
FILE 'USPAT2' ENTERED AT 12:23:04 ON 13 JAN 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

```
=> s l2 and pain
L3 1 L2 AND PAIN
```

```
=> d abs bib hitstr
```

```
L3 ANSWER 1 OF 1 USPATFULL
AB 2,4a-Ethanobenz[g]isoquinolin-5(1H)-one derivatives are described which
are useful as analgesic and anti-fertility agents.
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
AN 81:2388 USPATFULL
TI 2,4a-Ethanobenz[g]isoquinolin-5(1H)-ones and their use as anti-fertility
and analgesic agents
IN Farr, Robert A., Cincinnati, OH, United States
Dolfini, Joseph E., Cincinnati, OH, United States
PA Richardson-Merrell Inc., Wilton, CT, United States (U.S. corporation)
PI US 4244955 19810113
AI US 1979-34357 19790430 (6)
DT Utility
FS Granted
EXNAM Primary Examiner: Daus, Donald G.; Assistant Examiner: Springer, D. B.
LREP Stein, William J., Conte, Salvatore R.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1,4,5
```

Print selected from Online session13/01/2003

DRWN No Drawings

LN.CNT 467


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 76448-01-6P 76448-02-7P

(prepn. and pharmacol. activity of)


RN 76448-01-6 USPATFULL

CN 2,4a-Ethanobenz[g]isoquinolin-5(1H)-one, 3,4,10,10a-tetrahydro- (9CI) (CA INDEX NAME)



RN 76448-02-7 USPATFULL

CN 2,4a-Ethanobenz[g]isoquinolin-5(1H)-one, 3,4,10,10a-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

15.16

163.52

FILE 'CAPLUS' ENTERED AT 12:23:42 ON 13 JAN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Jan 2003 VOL 138 ISS 3

Print selected from Online session12:24Page 4

Print selected from Online session13/01/2003

FILE LAST UPDATED: 12 Jan 2003 (20030112/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 12:22:17 ON 13 JAN 2003)

FILE 'REGISTRY' ENTERED AT 12:22:32 ON 13 JAN 2003

L1 STRUCTURE UPLOADED
L2 188 S L1 FUL

FILE 'USPATFULL, USPAT2' ENTERED AT 12:23:04 ON 13 JAN 2003

L3 1 S L2 AND PAIN

FILE 'CAPLUS' ENTERED AT 12:23:42 ON 13 JAN 2003


=> s l2 and pain

23 L2
27373 PAIN
776 PAINS
27958 PAIN
(PAIN OR PAINS)

L4 2 L2 AND PAIN

=> d abs bib hitstr 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS
GI



AB The title compds. [I; R1 = H, OH; R2 = H, OH; or R1 and R2 together = O; A = a bond, CH2, CH(CH3), CH2CH2, C(CH3)2; R3, R4 = H, halo, alkyl, etc.; R5 = H, alkyl, alkenyl, etc.] and their salts which are potent antagonists of neuronal Na channels, as well as prostaglandin E2 (PGE2) prodn., and therefore are particularly useful for treating, among other indications, neuropathic pain and other CNS disorders such as seizures, were prepd. and formulated. E.g., a multi-step synthesis of I [A = CH2; R1 and R2 together = O; R3, R4 = H; R5 = cyclopropylmethyl] which showed Ki of 876 nM against Na+ channel binding in [3H]BTX assay, was given.

AN 2000:881127 CAPLUS

DN 134:42066

TI Preparation of spiro[naphthalene-2(1H),4'-piperidine] compounds as analgesics

IN Calvet, Alain; Jacobelli, Henri; Puaud, Jocelyne; Roman, Francois J.; Hamon, Jacques; Grouhel, Agnes

PA Warner-Lambert Co., USA

SO PCT Int. Appl., 59 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|--|----------|-----------------|----------|
| PI | WO 2000075116 | A2 | 20001214 | WO 2000-EP5783 | 20000607 |
| | WO 2000075116 | A3 | 20020704 | | |
| | W: | AE, AG, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | BR 2000011427 | A | 20020326 | BR 2000-11427 | 20000607 |
| | EP 1235808 | A2 | 20020904 | EP 2000-951290 | 20000607 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | |
| | NO 2001005966 | A | 20011206 | NO 2001-5966 | 20011206 |
| PRAI | US 1999-137868P | P | 19990607 | | |
| | WO 2000-EP5783 | W | 20000607 | | |
| OS | MARPAT 134:42066 | | | | |
| IT | 312599-84-1P | | | | |
| | RL: | BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) | | | |
| | | (prepn. of spiro[naphthalene-2(1H),4'-piperidine] compds. as analgesics) | | | |
| RN | 312599-84-1 | CAPLUS | | | |
| CN | Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-7-nitro- (9CI) (CA INDEX NAME) | | | | |




IT 136080-34-7P 152830-56-3P 152830-66-5P
 152830-86-9P 152830-89-2P 152830-94-9P
 205120-95-2P 312599-75-0P 312599-76-1P
 312599-77-2P 312599-78-3P 312599-79-4P
 312599-80-7P 312599-81-8P 312599-82-9P
 312599-83-0P 312599-85-2P 312599-86-3P
 312599-87-4P 312599-88-5P 312599-89-6P
 312599-90-9P 312599-91-0P 312599-92-1P
 312599-93-2P 312599-94-3P 312599-97-6P
 312599-98-7P 312599-99-8P 312600-00-3P
 312600-01-4P 312600-02-5P 312600-03-6P
 312600-04-7P 312600-05-8P 312600-06-9P
 312600-07-0P 312600-08-1P 312600-09-2P
 312600-10-5P 312600-11-6P 312600-12-7P
 312600-13-8P 312600-14-9P 312600-15-0P

312600-16-1P 312600-17-2P 312600-18-3P
312600-19-4P 312600-20-7P 312600-21-8P
312600-22-9P 312600-23-0P 312600-24-1P
312600-25-2P 312600-26-3P 312600-27-4P
312600-28-5P 312600-29-6P 312600-30-9P
312600-31-0P 312600-32-1P 312600-33-2P
312600-34-3P 312600-35-4P 312600-36-5P
312600-37-6P 312600-38-7P 312600-39-8P
312600-40-1P 312600-41-2P 312600-42-3P
312600-43-4P 312600-44-5P 312600-45-6P
312600-46-7P 312600-47-8P 312600-48-9P
312600-49-0P 312600-50-3P 312600-53-6P
312600-54-7P 312600-55-8P 312600-56-9P
312600-57-0P 312600-58-1P 312600-59-2P
312600-60-5P 312600-61-6P 312600-62-7P
312600-63-8P 312600-71-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of spiro[naphthalene-2(1H),4'-piperidine] compds. as analgesics)


RN 136080-34-7 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro- (9CI) (CA INDEX NAME)



RN 152830-56-3 CAPLUS


CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 152830-66-5 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 152830-86-9 CAPLUS


CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclohexylmethyl)-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 152830-89-2 CAPLUS


CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(2-phenylethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 152830-94-9 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 6-chloro-3,4-dihydro-1'-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 205120-95-2 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 312599-75-0 CAPLUS


CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312599-76-1 CAPLUS


CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclobutylmethyl)-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312599-77-2 CAPLUS


CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(2-cyclopropylethyl)-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



HCl

RN 312599-78-3 CAPLUS


CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(3-phenyl-2-propenyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312599-79-4 CAPLUS


CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(3,3-diphenylpropyl)-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 312599-80-7 CAPLUS


CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-5,7-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 312599-81-8 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 312599-82-9 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-5-methoxy-, hydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 312599-83-0 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-7-methoxy-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 312599-85-2 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 7-amino-1'-(cyclopropylmethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)






RN 312599-86-3 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 7-chloro-1'-(cyclopropylmethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 312599-87-4 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-methyl- (9CI) (CA INDEX NAME)




RN 312599-88-5 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 312599-89-6 CAPLUS


CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 312599-90-9 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylcarbonyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 312599-91-0 CAPLUS


CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-[(2-phenylcyclopropyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 312599-92-1 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-[bis(4-fluorophenyl)methyl]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 312599-93-2 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-ol, 1'-(cyclopropylmethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 312599-94-3 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidine], 1'-(cyclopropylmethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 312599-97-6 CAPLUS


CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-4-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 312599-98-7 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 6-chloro-1'-(cyclopropylmethyl)-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 312599-99-8 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-6-fluoro-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 312600-00-3 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-6,7-dimethoxy-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 312600-01-4 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(1-cyclopropylethyl)-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 312600-02-5 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(3-pentenyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 312600-03-6 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(3-phenylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 312600-04-7 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-6-methoxy-1'-(3-phenyl-2-propenyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 312600-05-8 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(2-cyclopropylethyl)-3,4-dihydro-5-methoxy- (9CI) (CA INDEX NAME)




RN 312600-06-9 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclobutylmethyl)-3,4-dihydro-5-methoxy- (9CI) (CA INDEX NAME)




RN 312600-07-0 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclohexylmethyl)-3,4-dihydro-5-methoxy- (9CI) (CA INDEX NAME)




RN 312600-08-1 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-5-methoxy-1'-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 312600-09-2 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-5-methoxy-1'-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 312600-10-5 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-5-methoxy-1'-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 312600-11-6 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(3,3-diphenylpropyl)-3,4-dihydro-5-methoxy- (9CI) (CA INDEX NAME)




RN 312600-12-7 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(2-cyclopropylethyl)-3,4-dihydro-6-methoxy- (9CI) (CA INDEX NAME)




RN 312600-13-8 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclobutylmethyl)-3,4-dihydro-6-methoxy- (9CI) (CA INDEX NAME)




RN 312600-14-9 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclohexylmethyl)-3,4-dihydro-6-methoxy- (9CI) (CA INDEX NAME)




RN 312600-15-0 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-6-methoxy-1'-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 312600-16-1 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-6-methoxy-1'-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 312600-17-2 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-6-methoxy-1'-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 312600-18-3 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(3,3-diphenylpropyl)-3,4-dihydro-6-methoxy- (9CI) (CA INDEX NAME)




RN 312600-19-4 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(2-cyclopropylethyl)-3,4-dihydro-7-methoxy- (9CI) (CA INDEX NAME)




RN 312600-20-7 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclobutylmethyl)-3,4-dihydro-7-methoxy- (9CI) (CA INDEX NAME)




RN 312600-21-8 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclohexylmethyl)-3,4-dihydro-7-methoxy- (9CI) (CA INDEX NAME)




RN 312600-22-9 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-7-methoxy-1'-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 312600-23-0 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-7-methoxy-1'-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 312600-24-1 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-7-methoxy-1'-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 312600-25-2 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(3,3-diphenylpropyl)-3,4-dihydro-7-methoxy- (9CI) (CA INDEX NAME)




RN 312600-26-3 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(2-cyclopropylethyl)-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 312600-27-4 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 312600-28-5 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclohexylmethyl)-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 312600-29-6 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-4-methyl-1'-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 312600-30-9 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-4-methyl-1'-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 312600-31-0 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-4-methyl-1'-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 312600-32-1 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(3,3-diphenylpropyl)-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 312600-33-2 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 6-chloro-1'-(2-cyclopropylethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 312600-34-3 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 6-chloro-1'-(cyclobutylmethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 312600-35-4 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 6-chloro-1'-(cyclohexylmethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 312600-36-5 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 6-chloro-3,4-dihydro-1'-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 312600-37-6 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 6-chloro-3,4-dihydro-1'-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 312600-38-7 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 6-chloro-1'-(3,3-diphenylpropyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 312600-39-8 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-6-methoxy- (9CI) (CA INDEX NAME)




RN 312600-40-1 CAPLUS


CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclobutylmethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 312600-41-2 CAPLUS


CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclohexylmethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)






RN 312600-42-3 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(2-cyclopropylethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 312600-43-4 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 312600-44-5 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(3,3-diphenylpropyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 312600-45-6 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-5,7-dimethyl- (9CI) (CA INDEX NAME)




RN 312600-46-7 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-6-methoxy- (9CI) (CA INDEX NAME)




RN 312600-47-8 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-5-methoxy- (9CI) (CA INDEX NAME)




RN 312600-48-9 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-7-methoxy- (9CI) (CA INDEX NAME)



RN 312600-49-0 CAPLUS


CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 312600-50-3 CAPLUS


CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-[(1R,2R)-2-phenylcyclopropylmethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 312600-53-6 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 6-chloro-1'-(cyclopropylmethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 312600-54-7 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-6-fluoro-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 312600-55-8 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)




RN 312600-56-9 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(1-cyclopropylethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 312600-57-0 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(3-pentenyl)- (9CI) (CA INDEX NAME)




RN 312600-58-1 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-1'-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 312600-59-2 CAPLUS

CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 312600-60-5 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidinium], 1'-(cyclopropylmethyl)-3,4-dihydro-1'-methyl-1-oxo-, iodide (9CI) (CA INDEX NAME)




● I⁻

RN 312600-61-6 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro-7-nitro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 312600-62-7 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 7-amino-1'-(cyclopropylmethyl)-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 312600-63-8 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 7-chloro-1'-(cyclopropylmethyl)-3,4-dihydro-, hydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 312600-71-8 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 1'-(cyclopropylmethyl)-3,4-dihydro- (9CI) (CA INDEX NAME)




IT 312600-70-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of spiro[naphthalene-2(1H),4'-piperidine] compds. as analgesics)

RN 312600-70-7 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-5,7-dimethyl- (9CI) (CA INDEX NAME)







IT 136080-33-6P 312600-64-9P 312600-65-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. of spiro[naphthalene-2(1H),4'-piperidine] compds. as
analgesics)
RN 136080-33-6 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidine]-1'-carboxylic acid,
3,4-dihydro-1-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 312600-64-9 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidine]-1'-carboxylic acid,
3,4-dihydro-7-nitro-1-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 312600-65-0 CAPLUS
CN Spiro[naphthalene-2(1H),4'-piperidin]-1-one, 3,4-dihydro-7-nitro- (9CI)
(CA INDEX NAME)



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS
GI



AB The title compds. I (R = H, alkyl, halo), useful as antifertility and analgesic agents, were prepd. Thus, 10.0 g 1-(3-phenyl-2-propenyl)-4-piperidinecarbonitrile, prepd. from isonipecotamide and ClCH₂CH:CHPh, was cyclized in the presence of LiNEt₂ to give 3.67 g 3-benzyl-1-azabicyclo[2.2.2]octane-4-carbonitrile, which was hydrolyzed to the carboxylic acid, whose cyclization in the presence of polyphosphoric acid at 120.degree. for 3 h gave, after treatment with HCl, I.HCl (R = H;II), which at 5 mg/kg s.c. relieved **pain** in 3 of 4 mice. Also, at 30.0 mg/kg s.c. II showed antifertility activity in 5 of the 8 female hamsters tested.

AN 1981:480737 CAPLUS

DN 95:80737

TI 2,4a-Ethanobenz[g]isoquinolin-5(1H)-ones and their use as anti-fertility and analgesic agents

IN Farr, Robert A.; Dolfini, Joseph E.

PA Richardson-Merrell Inc., USA

SO U.S., 6 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---------------|------|----------|-----------------|----------|
| PI | US 4244955 | A | 19810113 | US 1979-34357 | 19790430 |
| PRAI | US 1979-34357 | | 19790430 | | |


IT 76448-01-6P 76448-02-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and pharmacol. activity of)


RN 76448-01-6 CAPLUS

CN 2,4a-Ethanobenz[g]isoquinolin-5(1H)-one, 3,4,10,10a-tetrahydro- (9CI) (CA INDEX NAME)



RN 76448-02-7 CAPLUS

CN 2,4a-Ethanobenz[g]isoquinolin-5(1H)-one, 3,4,10,10a-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

=> s 17

L8 21 L7

=> s 18 and pain

L9 11 L8 AND PAIN

=> d abs bib fhitr 1-11

L9 ANSWER 1 OF 11 USPTFLL

AB Piperidine compounds having the general formula (I), ##STR1##

wherein R^{sup.1} is (a) a group consisting of alkyl, alkenyl, cycloalkyl, cycloalkenyl, phenyl, cycloalkylalkyl, cycloalkenylalkyl, phenylalkyl or diphenylalkyl linked to the piperidyl N-atom through an at least 2-membered spacer group; or (b) a group having general formula (II), ##STR2##

wherein X is CHR^{sup.10}, O, S, SO, SO_{sub.2} or NR^{sup.10}, Z^{sup.1} is CH_{sub.2}, O, or S; Z^{sup.2} and Z^{sup.3} are independently (CH_{sub.2})_{sub.n}, n being 0 or 1, O or S or Z^{sup.1} and Z^{sup.2} may together represent a group --CH_{dbd}.CH--; or when Z^{sup.3} is (CH_{sub.2})_{sub.n} wherein n is 0, Z^{sup.1} and Z^{sup.2} may together represent a 3-membered divalent group; show potent sigma receptor activity. Furthermore they show effect in animal models indicative of anxiolytic properties. Accordingly they are useful as medicines for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases, senile demential of the Alzheimer type or Parkinson's disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:44235 USPTFLL

TI Piperidine derivatives having anxiolytic effect

IN Moltzen, Ejner K., Frederiksberg C, Denmark

Perregaard, Jens Kristian, Jaegerspris, Denmark

PA H. Lundbeck A/S, Copenhagen-Valby, Denmark (non-U.S. corporation)

PI US 6207677 B1 20010327

AI US 1999-391290 19990907 (9)

RLI Continuation of Ser. No. US 1995-486510, filed on 7 Jun 1995, now patented, Pat. No. US 6031099 Division of Ser. No. US 1993-166647, filed on 13 Dec 1993, now patented, Pat. No. US 5665725 Continuation of Ser. No. WO 1992-DK183, filed on 12 Jun 1992

PRAI DK 1991-1129 19910613

DK 1991-1131 19910613

DK 1992-157 19920210

DT Utility

FS Granted

EXNAM Primary Examiner: Huang, Evelyn Mei

LREP Darby & Darby

CLMN Number of Claims: 8

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2119

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 147835-16-3P

(prepn. of, as .sigma.-receptor antagonist)


RN 147835-16-3 USPTFLL

CN Spiro[naphthalene-1(2H),4'-piperidine], 3,4-dihydro-1'-(4-phenylbutyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 147835-15-2

CMF C24 H31 N




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.



L9 ANSWER 2 OF 11 USPATFULL

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:4747 USPATFULL

TI Compounds having effects on serotonin-related systems

IN Audia, James E., Indianapolis, IN, United States
Hibschman, David J., Bargersville, IN, United States
Krushinski, Jr., Joseph H., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Nissen, Jeffrey S., Fishers, IN, United States
Rasmussen, Kurt, Fishers, IN, United States
Rocco, Vincent P., Indianapolis, IN, United States
Schaus, John M., Zionsville, IN, United States
Thompson, Dennis C., Indianapolis, IN, United States
Wong, David T., Indianapolis, IN, United States

PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

PI US 6172073 B1 20010109

AI US 1998-49837 19980327 (9)

RLI Division of Ser. No. US 1995-467434, filed on 6 Jun 1995, now patented,
Pat. No. US 5741789 Continuation-in-part of Ser. No. US 1995-373823,

filed on 17 Jan 1995, now abandoned
DT Patent
FS Granted
EXNAM Primary Examiner: Raymond, Richard L.
LREP Lentz, Nelsen L.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5343

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 180158-08-1P

(prepn. of 3-(4-indolyloxy)-2-hydroxypropanamines as serotonin 1A
receptor antagonists and partial agonists)

RN 180158-08-1 USPATFULL


CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-
hydroxy-3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 180158-07-0

CMF C25 H28 N2 O3


Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7

CMF C2 H2 O4



L9 ANSWER 3 OF 11 USPATFULL

AB Piperidine compounds having the general formula (I), ##STR1## wherein R.sup.1 is (a) a group consisting of alkyl, alkenyl, cycloalkyl, cycloalkenyl, phenyl, cycloalkylalkyl, cycloalkenylalkyl, phenylalkyl or diphenylalkyl linked to the piperidyl N-atom through an at least 2-membered spacer group; or (b) a group having general formula (II), ##STR2## wherein X is CHR.sup.10, O, S, SO, SO.sub.2 or NR.sup.10, Z.sup.1 is CH.sub.2, O, or S; Z.sup.2 and Z.sup.3 are independently (CH.sub.2).sub.n, n being 0 or 1, O or S or Z.sup.1 and Z.sup.2 may together represent a group --CH.dbd.CH--; or when Z.sup.3 is (CH.sub.2).sub.n wherein n is 0, Z.sup.1 and Z.sup.2 may together represent a 3-membered divalent group; show potent sigma receptor activity. Furthermore they show effect in animal models indicative of anxiolytic properties. Accordingly they are useful as medicines for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases, senile demential of the Alzheimer type or Parkinson's disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2000:24773 USPATFULL
TI Piperidine derivates having anxiolytic effect
IN Moltzen, Ejner K., Frederiksberg C, Denmark
Perregaard, Jens Kristian, Jaegerspris, Denmark
PA H. Lundbeck A/S, Copenhagen-Valby, Denmark (non-U.S. corporation)
PI US 6031099 20000229
AI US 1995-486510 19950607 (8)
RLI Division of Ser. No. US 166647
PRAI DK 1991-1129 19910613
DK 1991-1131 19910613
DK 1992-157 19920210
DT Utility
FS Granted
EXNAM Primary Examiner: Huang, Evelyn Mei
LREP Darby & Darby
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2042

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 147835-16-3P
(prepn. of, as .sigma.-receptor antagonist)


RN 147835-16-3 USPATFULL

CN Spiro[naphthalene-1(2H),4'-piperidine], 3,4-dihydro-1'-(4-phenylbutyl)-,
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 147835-15-2

CMF C24 H31 N




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.



L9 ANSWER 4 OF 11 USPATFULL

AB Piperidine compounds having the general formula (I), ##STR1## wherein R.sup.1 is (a) a group consisting of alkyl, alkenyl, cycloalkyl, cycloalkenyl, phenyl, cycloalkylalkyl, cycloalkenyalkyl, phenylalkyl or diphenylalkyl linked to the piperidyl N-atom through an at least 2-membered spacer group; or (b) a group having general formula (II), ##STR2## wherein X is CHR.sup.10, O, S, SO, SO.sub.2 or NR.sup.10, Z.sup.1 is CH.sub.2, O, or S; Z.sup.2 and Z.sup.3 are independently (CH.sub.2).sub.n, n being 0 or 1, O or S or Z.sup.1 and Z.sup.2 may together represent a group --CH.dbd.CH--; or when Z.sup.3 is (CH.sub.2).sub.n wherein n is 0, Z.sup.1 and Z.sup.2 may together represent a 3-membered divalent group; show potent sigma receptor activity. Furthermore they show effect in animal models indicative of anxiolytic properties. Accordingly they are useful as medicines for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases, senile demential of the Alzheimer type or Parkinson's disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1998:111951 USPATFULL

TI Piperidine derivatives having anxiolytic effect

IN Moltzen, Ejner K., Frederiksberg C, Denmark

Perregaard, Jens Kristian, Jaegerspris, Denmark

PA H. Lundbeck A/S, Copenhagen-Valby, Denmark (non-U.S. corporation)

PI US 5807871 19980915

AI US 1995-478563 19950607 (8)

RLI Division of Ser. No. US 1993-166647, filed on 13 Dec 1993

PRAI DK 1991-1129 19910613

DK 1991-1131 19910613

DK 1992-157 19920210

DT Utility

FS Granted

EXNAM Primary Examiner: Ivy, C. Warren; Assistant Examiner: Dahlen, Garth M.

LREP Darby & Darby

CLMN Number of Claims: 2

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2055

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 147835-16-3P

(prepn. of, as .sigma.-receptor antagonist)


RN 147835-16-3 USPATFULL

CN Spiro[naphthalene-1(2H),4'-piperidine], 3,4-dihydro-1'-(4-phenylbutyl)-,
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 147835-15-2

CMF C24 H31 N




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.



L9 ANSWER 5 OF 11 USPATFULL

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1998:92024 USPATFULL

TI Compounds having effects on serotonin-related systems

IN Audia, James E., Indianapolis, IN, United States

Hibschman, David J., Bargserville, IN, United States

Krushinski, Jr., Joseph H., Indianapolis, IN, United States

Mabry, Thomas E., Indianapolis, IN, United States

Nissen, Jeffrey S., Fishers, IN, United States

Rasmussen, Kurt, Fishers, IN, United States

Rocco, Vincent P., Indianapolis, IN, United States
Schaus, John M., Zionsville, IN, United States
Thompson, Dennis C., Indianapolis, IN, United States
Wong, David T., Indianapolis, IN, United States
PA Eli Lilly Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5789402 19980804
AI US 1995-471121 19950606 (8)
RLI Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995,
now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Berch, Mark L.; Assistant Examiner: Kifle, Bruck
LREP Palmberg, Arleen, Boone, David E.
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5961

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 180158-08-1P

(prepn. of heteroaryloxy alkanamines having effects on
serotonin-related systems)

RN 180158-08-1 USPATFULL


CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-
hydroxy-3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 180158-07-0

CMF C25 H28 N2 O3


Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7

CMF C2 H2 O4



L9 ANSWER 6 OF 11 USPATFULL

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1998:42357 USPATFULL

TI Compounds having effects on serotonin-related systems

IN Hibschan, David J., Bargsville, IN, United States
Krushinski, Jr., Joseph H., Indianapolis, IN, United States
Rasmussen, Kurt, Fishers, IN, United States
Rocco, Vincent P., Indianapolis, IN, United States
Schaus, John M., Zionsville, IN, United States
Thompson, Dennis C., Indianapolis, IN, United States

PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

PI US 5741789 19980421

AI US 1995-467434 19950606 (8)

RLI Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Kifle, Bruck

LREP Palmberg, Arleen, Boone, David E.

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 5902

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 180158-08-1P

(prepn. of heterocycloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)

RN 180158-08-1 USPATFULL


CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-hydroxy-3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 180158-07-0

CMF C25 H28 N2 O3


Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7

CMF C2 H2 O4



L9 ANSWER 7 OF 11 USPATFULL

AB Piperidine compounds having the general formula (I), ##STR1## wherein R.sup.1 is a group having general formula (II), ##STR2## wherein X is CHR.sup.10, O, S, SO, SO.sub.2 or NR.sup.10, Z.sup.1 is CH.sub.2, O, or S; Z.sup.2 and Z.sup.3 are independently (CH.sub.2).sub.n, n being 0 or 1, O or S or Z.sup.1 and Z.sup.2 may together represent a group --CH.dbd.CH--; or when Z.sup.3 is (CH.sub.2).sub.n wherein n is 0, Z.sup.1 and Z.sup.2 may together represent a 3-membered divalent group; show potent sigma receptor activity. Furthermore they show effect in animal models indicative of anxiolytic properties. Accordingly they are useful as medicines for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases, senile dementia of the Alzheimer type or Parkinson's disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 97:81274 USPATFULL

TI Piperidine derivatives having anxiolytic effect

IN Moltzen, Ejner K., Frederiksberg C, Denmark

Perregaard, Jens Kristian, Jaegerspars, Denmark

PA Lundbeck, H., Copenhagen-Valby, Denmark (non-U.S. individual)

PI US 5665725 19970909

AI US 1993-166647 19931213 (8)


PRAI DK 1991-1129 19910613

DK 1991-1131 19910613

DK 1992-157 19920210
DT Utility
FS Granted
EXNAM Primary Examiner: Chang, Ceila
LREP Darby & Darby
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2120
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 147835-16-3P
(prepn. of, as .sigma.-receptor antagonist)
RN 147835-16-3 USPATFULL
CN Spiro[naphthalene-1(2H),4'-piperidine], 3,4-dihydro-1'-(4-phenylbutyl)-,
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 147835-15-2
CMF C24 H31 N



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



L9 ANSWER 8 OF 11 USPATFULL
AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 97:38539 USPATFULL
TI Compounds having effects on serotonin-related systems
IN Audia, James E., Indianapolis, IN, United States

Hibschman, David J., Bargsville, IN, United States
Krushinski, Jr., Joseph H., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Nissen, Jeffrey S., Fishers, IN, United States
Rasmussen, Kurt, Fishers, IN, United States
Rocco, Vincent P., Indianapolis, IN, United States
Schaus, John M., Zionsville, IN, United States
Thompson, Dennis C., Indianapolis, IN, United States
Wong, David T., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.
corporation)
PI US 5627196 19970506
AI US 1995-468948 19950606 (8)
RLI Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995,
now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Bottino, Anthony
LREP Jones, Joseph A., Boone, David E.
CLMN Number of Claims: 56
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5947
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 180158-08-1P
(prepn. of heterocyclyoxyalkanamines as serotonin 1A antagonists and
reuptake inhibitors)
RN 180158-08-1 USPATFULL
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-
hydroxy-3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (salt) (9CI)
(CA INDEX NAME)

CM 1


CRN 180158-07-0
CMF C25 H28 N2 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



L9 ANSWER 9 OF 11 USPATFULL

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 97:25037 USPATFULL

TI Compounds having effects on serotonin-related systems

IN Audia, James E., Indianapolis, IN, United States
Krushinski, Jr., Joseph H., Indianapolis, IN, United States
Rasmussen, Kurt, Fishers, IN, United States
Rocco, Vincent P., Indianapolis, IN, United States
Schaus, John M., Zionsville, IN, United States
Thompson, Dennis C., Indianapolis, IN, United States
Wong, David T., Indianapolis, IN, United States

PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

PI US 5614523 19970325

AI US 1995-470512 19950606 (8)

RLI Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Bottino, Anthony

LREP Jones, Joseph A., Boone, David E.

CLMN Number of Claims: 19

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 5755

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 180158-08-1P

(prepn. of heteroaryloxy alkanamines having effects on serotonin-related systems)


RN 180158-08-1 USPATFULL

CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-hydroxy-3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 180158-07-0
CMF C25 H28 N2 O3


Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7

CMF C2 H2 O4



L9 ANSWER 10 OF 11 USPATFULL

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 96:106493 USPATFULL

TI Compounds having effects on serotonin-related systems

IN Krushinski, Jr., Joseph H., Indianapolis, IN, United States

Rasmussen, Kurt, Fishers, IN, United States

Rocco, Vincent P., Indianapolis, IN, United States

Schaus, John M., Zionsville, IN, United States

Thompson, Dennis C., Indianapolis, IN, United States

PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

PI US 5576321 19961119

AI US 1995-468900 19950606 (8)

RLI Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned

DT Utility


FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Bottino, Anthony
LREP Jones, Joseph A., Boone, David E.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5725
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 180158-08-1P

(prepn. and formulation of 4-(3-amino-2-hydroxypropoxy)indoles and
analogs as 5-HT1A receptor ligands)
RN 180158-08-1 USPATFULL
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-
hydroxy-3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 180158-07-0
CMF C25 H28 N2 O3

Absolute stereochemistry. Rotation (-).



analgesic activity, to processes for their manufacture and to compositions containing them. Typical of the dihydroanthracene derivatives disclosed is 6-chloro-4-hydroxy-1'-methyl-9,10-dihydroanthracene-9-spiro-4'-piperidine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 76:49488 USPATFULL
TI 1'-Substituted-9,10-dihydroanthracene-9-spiro-4'-piperidine derivatives
IN Galt, Ronald Hilson Begg, Macclesfield, England
Glen, Alasdair Thomas, Macclesfield, England
PA Imperial Chemical Industries Limited, London, England (non-U.S. corporation)
PI US 3979513 19760907
AI US 1975-541693 19750116 (5)
PRAI GB 1974-5018 19740204
DT Utility
FS Granted
EXNAM Primary Examiner: Trousof, Natalie
LREP Cushman, Darby & Cushman
CLMN Number of Claims: 10
ECL Exemplary Claim: 1,10
DRWN No Drawings
LN.CNT 1340

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 57996-26-6P
(prepn. and redn. of)
RN 57996-26-6 USPATFULL
CN Spiro[anthracene-9(10H),4'-piperidine]-2',6',10-trione, 1'-methyl- (9CI)
(CA INDEX NAME)

Print selected from Online session13/01/2003

FILE 'REGISTRY' ENTERED AT 12:22:32 ON 13 JAN 2003

L1 STRUCTURE UPLOADED
L2 188 S L1 FUL

FILE 'USPATFULL, USPAT2' ENTERED AT 12:23:04 ON 13 JAN 2003

L3 1 S L2 AND PAIN

FILE 'CAPLUS' ENTERED AT 12:23:42 ON 13 JAN 2003

L4 2 S L2 AND PAIN

FILE 'REGISTRY' ENTERED AT 12:27:06 ON 13 JAN 2003

L5 STRUCTURE UPLOADED
L6 3 S L5
L7 329 S L5 FUL

FILE 'USPATFULL, USPAT2' ENTERED AT 12:28:46 ON 13 JAN 2003

L8 21 S L7
L9 11 S L8 AND PAIN

=> s l8 and migraine
L10 6 L8 AND MIGRAINE

=> d abs bib fhitr 1-6

L10 ANSWER 1 OF 6 USPATFULL

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:4747 USPATFULL

TI Compounds having effects on serotonin-related systems

IN Audia, James E., Indianapolis, IN, United States
Hibschman, David J., Bargersville, IN, United States
Krushinski, Jr., Joseph H., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Nissen, Jeffrey S., Fishers, IN, United States
Rasmussen, Kurt, Fishers, IN, United States
Rocco, Vincent P., Indianapolis, IN, United States
Schaus, John M., Zionsville, IN, United States
Thompson, Dennis C., Indianapolis, IN, United States
Wong, David T., Indianapolis, IN, United States

PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

PI US 6172073 B1 20010109

AI US 1998-49837 19980327 (9)

RLI Division of Ser. No. US 1995-467434, filed on 6 Jun 1995, now patented, Pat. No. US 5741789 Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned

DT Patent

FS Granted

EXNAM Primary Examiner: Raymond, Richard L.

LREP Lentz, Nelsen L.

CLMN Number of Claims: 8

ECL Exemplary Claim: 1

DRWN No Drawings

Print selected from Online session12:33Page 1

LN.CNT 5343

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 180158-08-1P

(prepn. of 3-(4-indolyloxy)-2-hydroxypropanamines as serotonin 1A receptor antagonists and partial agonists)

RN 180158-08-1 USPATFULL


CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-hydroxy-3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 180158-07-0

CMF C25 H28 N2 O3


Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7

CMF C2 H2 O4



L10 ANSWER 2 OF 6 USPATFULL

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1998:92024 USPATFULL
TI Compounds having effects on serotonin-related systems
IN Audia, James E., Indianapolis, IN, United States
Hibschman, David J., Bargersville, IN, United States
Krushinski, Jr., Joseph H., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Nissen, Jeffrey S., Fishers, IN, United States
Rasmussen, Kurt, Fishers, IN, United States
Rocco, Vincent P., Indianapolis, IN, United States
Schaus, John M., Zionsville, IN, United States
Thompson, Dennis C., Indianapolis, IN, United States
Wong, David T., Indianapolis, IN, United States
PA Eli Lilly Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5789402 19980804
AI US 1995-471121 19950606 (8)
RLI Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995,
now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Berch, Mark L.; Assistant Examiner: Kifle, Bruck
LREP Palmberg, Arleen, Boone, David E.
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5961


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 180158-08-1P
(prepn. of heteroaryloxy alkanamines having effects on
serotonin-related systems)
RN 180158-08-1 USPATFULL
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-
hydroxy-3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 180158-07-0
CMF C25 H28 N2 O3


Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7

CMF C2 H2 O4



L10 ANSWER 3 OF 6 USPATFULL

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1998:42357 USPATFULL

TI Compounds having effects on serotonin-related systems

IN Hibschan, David J., Bargsville, IN, United States

Krushinski, Jr., Joseph H., Indianapolis, IN, United States

Rasmussen, Kurt, Fishers, IN, United States

Rocco, Vincent P., Indianapolis, IN, United States

Schaus, John M., Zionsville, IN, United States

Thompson, Dennis C., Indianapolis, IN, United States

PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

PI US 5741789 19980421

AI US 1995-467434 19950606 (8)

RLI Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Kifle, Bruck
LREP Palmberg, Arleen, Boone, David E.
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5902

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 180158-08-1P

(prepn. of heterocyclyoxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)

RN 180158-08-1 USPATFULL


CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-hydroxy-3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 180158-07-0

CMF C25 H28 N2 O3


Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7

CMF C2 H2 O4



L10 ANSWER 4 OF 6 USPATFULL

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of

serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 97:38539 USPATFULL
TI Compounds having effects on serotonin-related systems
IN Audia, James E., Indianapolis, IN, United States
Hibschman, David J., Bargersville, IN, United States
Krushinski, Jr., Joseph H., Indianapolis, IN, United States
Mabry, Thomas E., Indianapolis, IN, United States
Nissen, Jeffrey S., Fishers, IN, United States
Rasmussen, Kurt, Fishers, IN, United States
Rocco, Vincent P., Indianapolis, IN, United States
Schaus, John M., Zionsville, IN, United States
Thompson, Dennis C., Indianapolis, IN, United States
Wong, David T., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5627196 19970506
AI US 1995-468948 19950606 (8)
RLI Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Bottino, Anthony
LREP Jones, Joseph A., Boone, David E.
CLMN Number of Claims: 56
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5947


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 180158-08-1P
(prepn. of heterocycloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)
RN 180158-08-1 USPATFULL
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-hydroxy-3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 180158-07-0
CMF C25 H28 N2 O3


Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7

CMF C2 H2 O4



L10 ANSWER 5 OF 6 USPATFULL

AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 97:25037 USPATFULL

TI Compounds having effects on serotonin-related systems

IN Audia, James E., Indianapolis, IN, United States
 Krushinski, Jr., Joseph H., Indianapolis, IN, United States
 Rasmussen, Kurt, Fishers, IN, United States
 Rocco, Vincent P., Indianapolis, IN, United States
 Schaus, John M., Zionsville, IN, United States
 Thompson, Dennis C., Indianapolis, IN, United States
 Wong, David T., Indianapolis, IN, United States

PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

PI US 5614523 19970325

AI US 1995-470512 19950606 (8)

RLI Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned

DT Utility

FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Bottino, Anthony
LREP Jones, Joseph A., Boone, David E.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5755
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 180158-08-1P


(prepn. of heteroaryloxy alkanamines having effects on
serotonin-related systems)

RN 180158-08-1 USPATFULL
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-
hydroxy-3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (salt) (9CI)
(CA INDEX NAME)

CM 1


CRN 180158-07-0
CMF C25 H28 N2 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4



L10 ANSWER 6 OF 6 USPATFULL
AB A series of hetero-oxy alkanamines are effective pharmaceuticals for the

treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 96:106493 USPATFULL
TI Compounds having effects on serotonin-related systems
IN Krushinski, Jr., Joseph H., Indianapolis, IN, United States
Rasmussen, Kurt, Fishers, IN, United States
Rocco, Vincent P., Indianapolis, IN, United States
Schaus, John M., Zionsville, IN, United States
Thompson, Dennis C., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5576321 19961119
AI US 1995-468900 19950606 (8)
RLI Continuation-in-part of Ser. No. US 1995-373823, filed on 17 Jan 1995, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Bottino, Anthony
LREP Jones, Joseph A., Boone, David E.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 5725


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 180158-08-1P
(prepn. and formulation of 4-(3-amino-2-hydroxypropoxy)indoles and analogs as 5-HT1A receptor ligands)
RN 180158-08-1 USPATFULL
CN Spiro[naphthalene-1(2H),4'-piperidin]-2-one, 3,4-dihydro-1'-[(2S)-2-hydroxy-3-(1H-indol-4-yloxy)propyl]-, ethanedioate (1:1) (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 180158-07-0
CMF C25 H28 N2 O3


Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7

CMF C2 H2 O4



=>